Company intelligence / Profile preview

pSiMedica

London, England, United Kingdominvestors.eyepointpharma.com ↗

Ownership: Private
Development stage: Other

Overview

pSiMedica developed a proprietary platform based on porous silicon ("BioSilicon™") for use in therapeutic medical devices and advanced drug delivery. The company was acquired by pSivida Limited in 2004–2005 to accelerate development of this technology. No current clinical results are available as the entity has been dissolved since 2020.

Therapeutic areas: Other
Modalities: DeviceNanoparticleHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Partnerships

QinetiQ (UK government research agency)SGH Technology Ventures Pte LtdBiotech Research Ventures Pte Ltd

Beyond the preview

Go deeper on pSiMedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pSiMedica.

Explore the full profile